Tech Company Financing Transactions

Create Medicines Funding Round

Create Medicines, operating out of Cambridge, raised $122 million from Arch Venture Partners, Hatteras Venture Partners and Newpath Partners.

Transaction Overview

Company Name
Create Medicines
Announced On
5/14/2026
Transaction Type
Venture Equity
Amount
$122,000,000
Round
Series B
Investors

Arch Venture Partners (Lead Investor) (Brian Cuneo)

Hatteras Venture Partners (Lead Investor)

Newpath Partners (Lead Investor) (Tom Thomas)

Alexandria Venture Investments

Proceeds Purpose
The company intends to use the funds to advance its CD19-targeted in vivo CAR-T therapy (CRT-402) into clinical trials for autoimmune disease, expand its dual CAR CD19 x BCMA program, and progress its oncology pipeline.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
300 Technology Square 203
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
www.createmedicines.com
Email Address
[email protected]
Overview
CREATE Medicines is pioneering multi-immune programming with its versatile in vivo CAR platform. Our proprietary mRNA-LNP CARs and targeted receptor/LNP technologies enable direct programming of T cells, NK cells, and myeloid cells within the body. CREATE's in vivo CAR products have demonstrated first-in-human evidence of uptake, expression, and tolerable repeat dosing.
Profile
Create Medicines LinkedIn Company Profile
Social Media
Create Medicines Company Twitter Account
Company News
Create Medicines News
Facebook
Create Medicines on Facebook
YouTube
Create Medicines on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Daniel Getts
  Daniel Getts LinkedIn Profile  Daniel Getts Twitter Account  Daniel Getts News  Daniel Getts on Facebook
Chief Financial Officer
Brett Kaplan
  Brett Kaplan LinkedIn Profile  Brett Kaplan Twitter Account  Brett Kaplan News  Brett Kaplan on Facebook
Chief Financial Officer
Jason Walsh
  Jason Walsh LinkedIn Profile  Jason Walsh Twitter Account  Jason Walsh News  Jason Walsh on Facebook
Chief Medical Officer
Matthew Maurer
  Matthew Maurer LinkedIn Profile  Matthew Maurer Twitter Account  Matthew Maurer News  Matthew Maurer on Facebook
Chief Scientific Officer
Robert Hofmeister
  Robert Hofmeister LinkedIn Profile  Robert Hofmeister Twitter Account  Robert Hofmeister News  Robert Hofmeister on Facebook
Chief Technical Officer
Jerome Chal
  Jerome Chal LinkedIn Profile  Jerome Chal Twitter Account  Jerome Chal News  Jerome Chal on Facebook
Vice President
Michele Cioffi
  Michele Cioffi LinkedIn Profile  Michele Cioffi Twitter Account  Michele Cioffi News  Michele Cioffi on Facebook
Vice President
Heather Cohen
  Heather Cohen LinkedIn Profile  Heather Cohen Twitter Account  Heather Cohen News  Heather Cohen on Facebook
VP - Bus. Development
Adam Raff
  Adam Raff LinkedIn Profile  Adam Raff Twitter Account  Adam Raff News  Adam Raff on Facebook
VP - Human Resources
Curtis Demick
  Curtis Demick LinkedIn Profile  Curtis Demick Twitter Account  Curtis Demick News  Curtis Demick on Facebook
VP - R & D
Jian Ding
  Jian Ding LinkedIn Profile  Jian Ding Twitter Account  Jian Ding News  Jian Ding on Facebook

 

 

Browse more venture capital transactions:

Prev: 5/14/2026: Iceotope Technologies venture capital transaction
Next: 5/14/2026: DDD Invoices venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. VC transactions reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2026. Gaebler Ventures. All rights reserved.